Skymab Biotherapeutics is a CEA* spin-off biotech company committed to the design, engineering and development of antibodies targeting G Protein Coupled Receptors (GPCR) with a main focus in oncology.
Skymab was founded by enthusiastic scientists and entrepreneurs, thrilled to combine the most valuable technical knowledge in antibody discovery with their challenging know how in GPCR to create innovative tailored antibodies that achieved specific therapeutic strategies.
* French Atomic Agency (CEA), the most innovative public research organization in Europe according to a REUTERS ranking.
